Skip to content
GLP-1 Savers
Menu

Head-to-head · Value Score

CoreAge Rx vs PepHaūs

Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, PepHaūs a 79. Here's who gives you the honest lower price — and where each one bites back.

★ Better value

CoreAge Rx

#1 · Grade A+ · Best Value

Est. first month

$149/mo

Save ~89% vs brand-name
Get this deal Full CoreAge Rx review →
VS

PepHaūs

#78 · Grade B · Fair Price

Est. first month

From $152/mo (compounded)

Save ~89% vs brand-name
Get this deal Full PepHaūs review →

The verdict

Better value: CoreAge Rx

CoreAge Rx takes it on Value Score, 93 to 79 an est. $149/mo first month, with no teaser step-up baked in. PepHaūs isn't out of it: Shoppers who want all-inclusive compounded GLP-1 pricing shipped nationwide.

CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.

Deal-by-deal

The numbers that decide it. Green ✓ marks the stronger side on each line.

DealCoreAge RxPepHaūs
Value Score93 (A+)79 (B)
Est. first month$149/moFrom $152/mo (compounded)
Save vs brand-name~89%~89%
Semaglutide$149/moFrom $152/mo (compounded)
Tirzepatide$349/moFrom $246/mo (compounded)
Both moleculesYesYes
PricingFlat — no step-upWatch
CoverageAll 50 statesAll 50 states

Factor by factor

The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.

88
Lowest Real Price
81
CoreAge Rx: 88. PepHaūs: 81.
98
No Teaser-Rate Bait
62
CoreAge Rx: 98. PepHaūs: 62.
98
Nationwide Availability
96
CoreAge Rx: 98. PepHaūs: 96.
95
Both Molecules
92
CoreAge Rx: 95. PepHaūs: 92.
95
Easy Cancellation
68
CoreAge Rx: 95. PepHaūs: 68.
84
Reputation
77
CoreAge Rx: 84. PepHaūs: 77.

CoreAge Rx

The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.

Why it's a deal

  • Flat, all-in monthly price with no intro-rate step-ups after month one
  • Both compounded semaglutide and tirzepatide on one account
  • Available in all 50 states
  • Straightforward, low-friction cancellation — no lock-in

The fine print

  • Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
  • No FDA-approved brand-name option (compounded only)
  • Does not yet publicly name its 503A/B pharmacy partner

PepHaūs

PepHaūs is a telehealth pharmacy offering compounded GLP-1 weight-loss treatment — semaglutide from $152/mo and tirzepatide from $246/mo — prescribed by U.S.-licensed providers and shipped from 503A…

Why it's a deal

  • All-inclusive pricing — medication, medical visit, and shipping bundled into one cost
  • Compounded semaglutide from $152/mo (quarterly) and tirzepatide from $246/mo
  • LegitScript-certified (#50233613); 503A-compounded medication
  • Ships to all 50 states from U.S.-licensed 503A pharmacies
  • Quick online intake with 24-hour provider review

The fine print

  • Compounding pharmacy partners aren't named on the marketing site
  • Pricing is customized per patient, so your final cost can vary from the advertised 'from' rates
  • No published individual clinician or medical-director names
  • Newer multi-vertical brand (also NAD+, sermorelin, glutathione) with a limited weight-loss track record
Get the CoreAge Rx deal Get the PepHaūs deal

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.

Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to PepHaūs.

More head-to-heads

← All comparisons

Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.